The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of $[^{18}\text{F}]$-FDOPA imaging in schizophrenia

Ilinca Angelescu$^{1,2,*}$, Stephen J Kaar$^{1,*}$, Tiago Reis Marques$^{1,3}$, Faith Borgan$^1$, Mattia Veronesse$^{1,4}$, Alice Sharman$^5$, Anil Sajjala$^5$, Bill Deakin$^6$, John Hutchison$^5$, Charles Large$^5$ and Oliver D Howes$^{1,3}$

Abstract

Background: Current treatments for schizophrenia act directly on dopamine (DA) receptors but are ineffective for many patients, highlighting the need to develop new treatment approaches. Striatal DA dysfunction, indexed using $[^{18}\text{F}]$-FDOPA imaging, is linked to the pathoetiology of schizophrenia. We evaluated the effect of a novel drug, AUT00206, a Kv3.1/3.2 potassium channel modulator, on dopaminergic function in schizophrenia and its relationship with symptom change. Additionally, we investigated the test–retest reliability of $[^{18}\text{F}]$-FDOPA PET in schizophrenia to determine its potential as a biomarker for drug discovery.

Methods: Twenty patients with schizophrenia received symptom measures and $[^{18}\text{F}]$-FDOPA PET scans, before and after being randomised to AUT00206 or placebo groups for up to 28 days treatment.

Results: AUT00206 had no significant effect on DA synthesis capacity. However, there was a correlation between reduction in striatal dopamine synthesis capacity (indexed as Kicer) and reduction in symptoms, in the AUT00206 group ($r=0.58$, $p=0.03$). This was not observed in the placebo group ($r=-0.15$, $p=0.75$), although the placebo group may have been underpowered to detect an effect. The intraclass correlation coefficients of $[^{18}\text{F}]$-FDOPA indices in the placebo group ranged from 0.83 to 0.93 across striatal regions.

Conclusions: The relationship between reduction in DA synthesis capacity and improvement in symptoms in the AUT00206 group provides evidence for a pharmacodynamic effect of the Kv3 channel modulator. The lack of a significant overall reduction in DA synthesis capacity in the AUT00206 group could be due to variability and the low number of subjects in this study. These findings support further investigation of Kv3 channel modulators for schizophrenia treatment. $[^{18}\text{F}]$-FDOPA PET imaging showed very good test–retest reliability in patients with schizophrenia.

Keywords

F-DOPA, reliability, test–retest, schizophrenia, Kv3, AUT00206

Introduction

Schizophrenia is a common and severe mental illness with a lifetime prevalence of approximately 0.7% (McCutcheon et al., 2019). It is characterised by positive psychotic symptoms, such as delusions and hallucinations, negative symptoms, such as social withdrawal and amotivation, and impairment in cognitive domains, including attention, working memory, verbal learning and executive function (McCutcheon et al., 2020b). It is a leading cause of adult disease burden (Whiteford et al., 2013) with substantial healthcare and societal costs (Howes and Murray, 2014), which approach 100 billion Euros per year across Europe (Gustavsson et al., 2011). It has been ranked 12th in the top global causes of disability for the last decade (Vos et al., 2016).

Dysregulated striatal dopamine (DA) function is thought to contribute to the development of schizophrenia (Abi-Dargham, 2017; Howes et al., 2015; McCutcheon et al., 2019). Several, $[^{18}\text{F}]$-FDOPA PET imaging studies have reported increased striatal dopamine synthesis capacity in patients with schizophrenia, with large effect sizes (Howes et al., 2011a, 2011b; McCutcheon et al., 2019; Reith et al., 1994). Meta-analysis suggests that increases are localised to the associative striatum; a striatal region...
connected to associative cortical regions such as the dorso-lateral prefrontal cortex (McCutcheon et al., 2018). Studies report that greater striatal DA synthesis capacity in the associative striatum directly correlates with more severe symptoms, predicts greater improvement with a D2 receptor blocking drugs, and is increased in patients with prodromal symptoms (Howes et al., 2011a, 2011b; Jauhar et al., 2017, 2019b). These findings suggest that DA synthesis capacity in the associative striatum measured using $[^{18}F]$-FDOPA PET may be a useful biomarker of the pathophysiology of schizophrenia with predictive potential for treatment selection (Bose et al., 2008). However, while $[^{18}F]$-FDOPA imaging shows good test–retest reliability in healthy volunteers (Egerton et al., 2010), its reliability in patients with schizophrenia is not known. In view of this, one of the study aims was to determine the test–retest reliability of $[^{18}F]$-FDOPA PET imaging in patients with schizophrenia.

Current pharmacological treatments for schizophrenia all act on D2 receptors, with the main effect being the reduction of positive symptoms (Miyamoto et al., 2012). They have little effect on negative and cognitive symptoms, and approximately 30% of patients show only partial benefit (Howes et al., 2017). Moreover, they act downstream of the pathophysiological increase in DA synthesis and release capacity (Howes et al., 2012), and, perhaps as a result, are not able to normalise this underlying abnormality (Howes et al., 2013; Jauhar et al., 2019a). This highlights the need for new therapeutic strategies.

It has been hypothesised that deficits in the function of GABA interneurons, particularly fast-spiking, parvalbumin (PV)-positive interneurons, may lead to the observed dopaminergic dysfunction, which in turn contributes to the symptoms of schizophrenia (Grace, 2016; Kaar et al., 2019; Lewis et al., 2012; McCutcheon et al., 2020a). Supporting this, psychotomimetic doses of drugs, such as ketamine and PCP, that block NMDA receptors expressed on GABA interneurons and which, when given chronically, reduced levels of PV in animals (Neill et al., 2010; Pratt et al., 2008), and, when given acutely, induce psychotic and negative symptoms in healthy people and worsen symptoms in patients with schizophrenia (Abdallah et al., 2018; Beck et al., 2019, 2020; Haaf et al., 2018; Thieba et al., 2017).

Moreover, ketamine elevates striatal DA synthesis capacity in mice, and this effect can be blocked by selectively activating PV-positive interneurons (Kokkinou et al., 2020). Post-mortem studies of brains from patients with schizophrenia show GABA-related alterations, especially for the specific subpopulation of PV-positive interneurons (Berretta et al., 2015; Chung et al., 2016; Dong et al., 2015; Enwright et al., 2016; Schubert et al., 2015), with a reduction in measures of PV seen on meta-analysis (Kaar et al., 2019), and lower levels of GABA markers seen in vivo (Frankle et al., 2015; Marques et al., 2020). GABA interneurons, particularly PV-positive cells, are regulated by Kv3.1 and Kv3.2 potassium channels, which are highly expressed in corticostriatal brain networks (Yanagi et al., 2014). Kv3.1 protein and mRNA expression were reduced in a post-mortem study in a cohort of patients with schizophrenia (Lewis et al., 2012; Yanagi et al., 2014). The reduction in Kv3.1 was only seen in patients that had not been on antipsychotic medication at the time of death. Kv3.1 channels are also expressed by neurons in the basal ganglia, which can regulate DA neuron firing (Parekh et al., 2018). Activation of Kv3.1 channels is proposed to enhance the firing of GABA neurons in these systems to increase inhibition of DA neurons in the basal ganglia and restore the balance of excitation–inhibition in higher cortical circuits (Parekh et al., 2018). Modulation of Kv3.1 channels may therefore provide a novel approach to restore the balance of activity within the DA system and thus reduce symptoms in patients with schizophrenia.

A series of novel, selective modulators of Kv3.1 and Kv3.2 channels has been identified, which can enhance the activity of PV-positive interneurons in vitro (Andrade-Talavera et al., 2020; Boddum et al., 2017; Rosato-Siri et al., 2015). In a study in mice, one of these compounds, AUT1, reduced amphetamine-induced hyperactivity, similar to the antipsychotic clozapine (Parekh et al., 2018). Moreover, AUT1 significantly reduced the firing rate of DA neurons (Parekh et al., 2018). AUT02006, similar to AUT1 (Rosato-Siri et al., 2015), modulates the voltage-dependence of activation of Kv3.1 and Kv3.2 ion channels. The compound lowers the voltage at which these channels are activated and thus facilitates channel opening at more hyperpolarised potentials (Autifony, unpublished data). Consistent with these effects on Kv3.1 and Kv3.2 channels, studies in animal models have shown that AUT02006 can enhance the activity of PV-positive interneurons to rescue gamma frequency cortical and hippocampal network synchrony in vitro (Large et al., 2017), and impaired cognitive function in vivo (Leger et al., 2015). Cross-screening studies indicate that AUT02006 is highly selective for Kv3 channels, with little or no effect on other ion channels, receptors or enzymes examined (Autifony, unpublished data).

AUT02006 has been shown to influence the firing of PV-positive interneurons in vitro and rescue deficits in cognitive and PV expression in rats previously treated with PCP (Lodge, 2017). In a recent clinical study, AUT02006 post-treatment reduced the effect of ketamine on the fMRI BOLD signal in healthy human volunteers (Deakin et al., 2019). In view of this evidence, we aimed to test whether AUT02006 could influence DA synthesis capacity in patients with schizophrenia, measured using $[^{18}F]$-FDOPA PET, and whether this might relate to clinical change (Hutchison et al., 2019). We tested the hypothesis that AUT02006 would reduce DA synthesis capacity in the associative striatum and that greater reduction would be correlated with reduction in total symptom severity measured with the PANSS.

**Materials and method**

**Participants**

Twenty-four volunteers were recruited from psychosis early intervention services in London, England. The inclusion criteria were as follows: (1) male gender (due to the absence of safety data for AUT02006 in females), (2) diagnosis of schizophrenia as determined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) using the Structured Clinical Interview for DSM-5 (SCID-5) (First, 2016), (3) able to give informed consent, (4) within 5 years of illness diagnosis, (5) currently stable with no evidence of relapse within the last 2 months prior to study enrolment, (6) currently taking a stable dose of antipsychotic medication for at least 1 month (or had received at least three injections at the same dose if on depot), (7) symptom severity on the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) of at least three on two items of both the positive and negative symptom scales or severity of at least four on one item in the
positive, and (8) agreeing to use contraceptive measures for the duration of the trial.

The main exclusion criteria were as follows: (1) current or prior use of clozapine, (2) being severely underweight (body mass index (BMI) under 17.5) or morbidly obese (BMI over 35), (3) positive for HIV or hepatitis B or C, (4) positive for illicit drug use on urine drug test, (5) sensitivity to the study medication or placebo constituents, (6) history of significant adverse reactions to other drugs, (7) history of epilepsy or seizures, (8) type 1 or 2 diabetes, (9) suicidal or homicidal ideation or behaviour, (10) participation in a clinical trial within the last 30 days, (11) history of alcohol or drug dependence in the past year, (12) moderate depression or anxiety indicated by a score of ≥11 out of 21 on the Hospital Anxiety and Depression Scale (HADS) and (13) contraindications to imaging. Treatment resistance was not an exclusion criterion.

Design

This present report describes the design, implementation and results for the $^{18}$F-FDOPA PET biomarker measurements, conducted as part of a study to explore the safety, tolerability and pharmacokinetics of AUT00206 in patients with schizophrenia stabilised on up to two antipsychotic medications (EudraCT: 2016-002704-63). A placebo group was included for drug safety monitoring, not for a formal comparison of imaging biomarkers with placebo. Side effects and potential adverse events will be published in a separate report and are beyond the scope of the present work.

The aims for the $^{18}$F-FDOPA biomarker exploration were (1) to determine whether AUT00206 could alter DA synthesis capacity in these patients, (2) to determine whether any change in DA synthesis capacity might be related to changes in symptom measured with the PANSS and (3) to evaluate the test–retest reliability of $^{18}$F-FDOPA imaging in patients with schizophrenia. Our prior studies have shown that DA synthesis capacity in the associative striatum is elevated in patients with schizophrenia with an effect size of 1.1 to 1.3 (Howes et al., 2013; Jauhar et al., 2019a). A power calculation using G*power 3.1 (Faul et al., 2009) indicated that a sample size of 12 would have greater than 90% power to detect a significant reduction due to AUT00206 of this magnitude using a paired $t$-test ($p < 0.05$ two tailed) and a sample size of seven would have greater than 80% power to detect an intraclass correlation coefficient (ICC) of >0.8 in the placebo group. Subjects were scanned at baseline and were then randomised on a 2:1 basis to active treatment or placebo groups. They received AUT00206 or placebo treatment for up to 28 consecutive days. Treatment was added to their current antipsychotic pharmacokinetics of AUT00206 in patients with schizophrenia as this region is associated with the largest dopaminergic changes as this region is associated with the largest dopaminergic changes. Our primary region-of-interest was the associative striatum (Martinez, 2003) was nonlinearly coregistered. Our prior studies have shown that DA synthesis capacity in the associative striatum is elevated in patients with schizophrenia following antipsychotic treatment (McCutcheon et al., 2018).

Clinical measures

Psychiatric assessments included the PANSS, the HADS, the Clinical Global Impressions Scale and the Columbia-Suicide Severity Rating Scale. All patients received these measures at baseline and at day 28 on-treatment (or at dropout if earlier).

DA synthesis capacity: $^{18}$F-FDOPA PET imaging

All participants were asked to fast (except water) 12 h before the scan. Imaging data were collected on a Siemens Biograph 6 HiRez PET scanner (Siemens, Erlangen, Germany) in 3D mode in line with our standard procedure (Egerton et al., 2010; Howes et al., 2009). Subjects received 400 mg entacapone (a peripheral catechol-omethyl-transferase inhibitor) and 150 mg carbidopa (a peripheral aromatic acid decarboxylase inhibitor) orally 1 h before the scan to prevent the formation of radiolabelled metabolites that might cross the blood–brain barrier (Cuming et al., 1993). Participants were positioned with the orbitomeatal line parallel to the transaxial plane of the tomograph scanner. Head position was marked, monitored throughout the scan and movement minimized using a head strap. After acquiring a CT scan for attenuation correction, approximately 150 MBq of $^{18}$F-FDOPA was administered by bolus intravenous injection. PET data were acquired in 32 frames of increasing duration over the 95 min scan (frame intervals: 8 × 15 s, 3 × 60 s, 5 × 120 s, 16 × 300 s).

Image analysis

A region-of-interest (ROI) analysis was conducted to measure Ki$^{\text{exo}}$ (Ki in previous publications; Howes et al., 2013), using MATLAB R2018b (MATLAB, 2018), SPM12 and Piwave (Turkheimer et al., 1999). To correct for motion in the scanner, frames were realigned using the non-attenuation corrected images in combination with a level 2 order 64 Battle Lemaire wavelet filter. The transformation parameters were then applied to the corresponding attenuation-corrected images. For each subject, the movement-corrected dynamic frames were summed over time to define an individual brain PET space to which the Martinez striatal atlas (Martinez, 2003) was nonlinearly coregistered. Our primary region-of-interest was the associative striatum as this region is associated with the largest dopaminergic changes in schizophrenia, and Ki$^{\text{exo}}$ in this region predicts improvement following antipsychotic treatment (McCutcheon et al., 2018).

Data for the whole striatum and other subdivisions are reported for completeness. We used the striatal functional subdivisions (i.e. bilateral whole striatum, limbic, associative and sensorimotor subregions) defined as described by Martinez and colleagues.
(Martinez, 2003) together with a tracer specific template (Egerton et al., 2010; Howes et al., 2009) to create an ROI map, with the cerebellum as the reference region as defined by Egerton and colleagues (Egerton et al., 2010). Ki\textsuperscript{[18F]-FDOPA} was calculated for the whole striatal ROI and the bilateral functional subdivisions using the Patlak-Gjedde graphical approach adapted for a reference tissue input function (Egerton et al., 2010).

**Statistical analysis**

Data were analysed using SPSS version 22 (IBM Corp, Chicago, Illinois, USA). Data normality and sphericity were assessed using the Shapiro–Wilk test and the Mauchly’s test of sphericity, respectively. Categorical clinical, demographic and experimental variables were assessed using \( \chi^2 \) tests, while continuous variables were assessed using t-tests. Effect sizes were reported using Hedge’s \( g \), as it is more robust for small sample sizes. Hedge’s \( t \)-tests were assessed using \( t \)-tests. Effect sizes were reported using \( \text{CV} = \frac{\text{SD}}{\text{mean}} \times 100 \). Variance between subjects was expressed as percentage coefficient of variation (CV): \( \text{CV} = \frac{\text{SD}}{\text{mean}} \times 100 \).

**Results**

**Demographics and experimental variables**

A total of 24 volunteers took part in the study, of whom 20 completed both baseline and on-treatment scans (13 in the AUT00206 group and 7 in the placebo group). Four participants withdrew from the on-treatment scans due to claustrophobia. Demographic information and scan parameters are summarised in Table 1.

**The effect of AUT00206 on striatal dopaminergic function**

Figure 1 shows the Ki\textsuperscript{[18F]-FDOPA} values for the associative striatum at baseline and on-treatment, in the AUT00206 group. Data were normally distributed and sphericity assumptions were met for associative striatal Ki\textsuperscript{[18F]-FDOPA} values. There was no significant difference between baseline and on-treatment Ki\textsuperscript{[18F]-FDOPA} values in the associative striatum in the AUT00206 group (M\text{baseline} = 0.0180, SD = 0.001; M\text{on-treatment} = 0.0184, SD = 0.002; \( t \)-value = −1.05; \( p \) = 0.32, 95% CI = [−0.0012, 0.0004], \( g \) = 0.214) or other striatal regions (see supplementary material). Similarly, there was no significant difference between baseline and on-treatment Ki\textsuperscript{[18F]-FDOPA} values in the associative striatum in the placebo group (M\text{baseline} = 0.0196, SD = 0.002; M\text{on-treatment} = 0.0198, SD = 0.002; \( t \)-value = −0.28; \( p \) = 0.79, 95% CI = [−0.0016, 0.0013], \( g \) = 0.11).

We conducted an exploratory comparison of the placebo and AUT00206 groups. This showed there was no significant effect of treatment group (\( F_{1,18} = 3.32, p = 0.08 \)), time (\( F_{1,18} = 0.7, p = 0.41 \)) and no significant treatment group \( \times \) time interaction (\( F_{1,18} = 0.12, p = 0.72 \)) on Ki\textsuperscript{[18F]-FDOPA} values in the associative striatum or in the other striatal regions (see supplementary material).
Table 1. Demographic and clinical sample characteristics.

|                      | AUT00206                  | Placebo                  |
|----------------------|---------------------------|--------------------------|
|                      | Baseline, N=13            | Baseline, N=7            | On-treatment, N=7 | On-treatment, N=7 |
| Days between scans, Mean (SD) | 19.92 (4.5)  | 25.33 (10.48)  |
|                       | Range: 20–44 days         | Range: 16–45 days        |
| Age (years), Mean (SD) | 29.13 (6.51)             | 29.12 (10.75)            |
|                       | Range: 20–44 days         | Range: 16–45 days        |
| Weight (kg), Mean (SD) | 84.43 (25.20)            | 83.02 (34.97)            |
|                       | Range: 61–124             | Range: 60–160            |
| Dose of radioactivity (MBq), Mean (SD) | 146.85 (29.58) | 130.47 (48.95) |
|                       | Range: 86–225             | Range: 68–225            |
| Injected mass of radiotracer (μg), Mean (SD) | 1.25 (0.45)  | 1.06 (0.62)  |
|                       | Range: 0.01–3.00          | Range: 0.01–3.00         |
| SA (GBq/μmol), Mean (SD) | 0.03 (0.01)              | 0.03 (0.01)              |
|                       | Range: 0.01–0.03          | Range: 0.01–0.03         |
| PANSS positive, Mean (SD) | 19.86 (4.57)             | 19.14 (4.16)             |
|                       | Range: 13–35              | Range: 13–35             |
| PANSS negative, Mean (SD) | 20.36 (4.20)             | 20.00 (4.16)             |
|                       | Range: 15–32              | Range: 15–32             |
| PANSS general, Mean (SD) | 39.36 (4.85)             | 37.29 (4.19)             |
|                       | Range: 29–57              | Range: 26–59             |
| PANSS total, Mean (SD) | 79.57 (11.71)            | 76.43 (8.10)             |
| Medication            |                           |                          |
| CPZ equivalent dose/mg per day, Mean (SD) | 252.6 (148.6) | 181.6 (80.0) |
| First-generation antipsychotic N | 2                      | 0                       |
| Second-generation antipsychotic | 6                    | 5                       |
| Third-generation antipsychotic | 4                    | 2                       |
| Combination antipsychotics | 1                    | 0                       |

CPZ: chlorpromazine; GBq: gigabecquerel; kg: kilograms; MBq: megabecquerel; μg: microgram; mg: miligram; mm: millimetres; N: number; PANSS: Positive and Negative Syndromes Scale; SA: specific activity.

Figure 1. Associative striatal Ki<sup>corr</sup> values at baseline and on-treatment (M=19.92 days on-treatment, SD=4.5), shown separately for each subject in the AUT00206 group. There was no significant change over time (p=0.3).
Change in symptom severity and relationship to dopaminergic function

Table 1 shows the symptom ratings at baseline and on-treatment for the two groups. In the AUT00206 group, there was a significant reduction from baseline to on-treatment assessments of PANSS positive score ($t_{13} = 4.75, p = 0.001, 95\%\ CI = [2.11, 5.61], g = 0.782$), general psychopathy score ($t_{13} = 6.37, p < 0.001, 95\%\ CI = [3.64, 7.36], g = 1.089$) and total scores ($t_{13} = 5.59, p < 0.001, 95\%\ CI = [6.88, 14.70], g = 0.89$), but no significant change in PANSS negative scores ($t_{13} = 1.64, p = 0.48, 95\%\ CI = [-0.45, 3.31], g = 0.27$), although it should be noted that, in absolute terms, there were similar reductions in the placebo group as well (Table 1). There was a significant positive correlation between reduction in the associative striatal $K_i^{estr}$ and reduction in PANSS total ratings ($r = 0.59, p = 0.03$). In exploratory analyses, we found a significant positive correlation between associative striatal $K_i^{estr}$ change and reduction in PANSS positive ratings ($r = 0.56, p = 0.04$), but not for the general or negative ratings, in the AUT00206 group. For completeness, we explored the relationship between change in the other striatal regions and PANSS change, finding no significant associations (See supplementary material).

No significant changes in symptom scores were observed in the placebo group for PANSS positive ($t_6 = 1.54, p = 0.46, 95\%\ CI = [-1.25, 5.54], g = 0.70$), negative ($t_6 = 2.00, p = 0.36, 95\%\ CI = [-0.61, 6.04], g = 0.65$), general ($t_6 = 1.54, p = 0.68, 95\%\ CI = [-1.69, 7.40], g = 0.80$) or total ($t_6 = 1.81, p = 0.44, 95\%\ CI = [-2.68, 18.11], g = 0.94$) scores, and there was no significant relationship between change in symptom ratings and $K_i^{estr}$ values in the associative or other striatal regions. In an exploratory group comparison, there was a significant effect of time ($F_{1,18} = 36.84, p < 0.0001$), but no significant time $\times$ group interaction for any PANSS scale.

Test–retest reliability of $[^{18}\text{F}]$-FDOPA in the placebo group

The mean time between baseline and on-treatment scans was 25.33 days (SD = 10.48). Figure 3 shows whole striatal $K_i^{estr}$ values at baseline and on-treatment for each participant. There was no significant difference between the two timepoints in the striatal $K_i^{estr}$ values ($t_6 = -0.55, p = 0.60, 95\%\ CI = [-0.0017, 0.0010], g = -0.14$). The $K_i^{estr}$ values, interclass correlations and variance data are shown in Table 2.

Discussion

Our first main finding is that reduction in associative striatal $K_i^{estr}$ was associated with improvement in positive and total symptoms in the AUT00206 treated group, although there was no overall group effect of AUT00206 on $K_i^{estr}$. Our second main finding is that striatal $K_i^{estr}$ can be measured with very good test–retest reliability (ICC $> 0.83$) in patients with schizophrenia over a ~1-month interval using $[^{18}\text{F}]$-FDOPA PET imaging. This extends the work by Egerton and colleagues (Egerton et al., 2010) in healthy volunteers to show good-to-very good test–retest reliability (ICC $> 0.83$) in patients with schizophrenia over a ~1-month interval using $[^{18}\text{F}]$-FDOPA PET imaging.

This extends the work by Egerton and colleagues (Egerton et al., 2010) in healthy volunteers to show good-to-very good test–retest reliability of $[^{18}\text{F}]$-FDOPA PET imaging for determining $K_i^{estr}$ in the whole striatum and its functional subdivisions to patients with schizophrenia. The ICC values we report for whole striatum and associative striatum are similar to the values reported by Egerton et al. in healthy volunteers, indicating similar reliability in patients with schizophrenia. These data support the use of $[^{18}\text{F}]$-FDOPA PET imaging as a biomarker of DA synthesis capacity in patients with schizophrenia and suggest that it could be used to explore potential treatment effects, at least over a 1-month period.

Preclinical animal model studies suggest that Kv3 channel positive modulation might influence the function of the dopamine
Angelescu et al.

Figure 3. Whole striatal $K_i^{\text{est}}$ (min$^{-1}$) estimates at baseline and on-treatment (placebo) timepoints ($M=25.33$ days later, $SD=10.48$) in the placebo group. There was no significant change over time ($p=0.6$).

Table 2. ICC, CV and VAR for the whole striatum and its functional subdivisions before and after treatment with placebo.

| Region               | Test $K_i^{\text{est}}$ (min$^{-1}$) ($M \pm SD$) | CV (%) | Retest $K_i^{\text{est}}$ (min$^{-1}$) ($M \pm SD$) | CV (%) | ICC   | %VAR ($M \pm SD$) |
|----------------------|--------------------------------------------------|--------|--------------------------------------------------|--------|-------|-------------------|
| Whole striatum       | 0.0196 ± 0.0017                                  | 9.12   | 0.0199 ± 0.0019                                  | 9.82   | 0.84  | 1.44 ± 6.99       |
| Sensorimotor striatum| 0.0198 ± 0.0017                                  | 9.05   | 0.0205 ± 0.0024                                  | 12.06  | 0.86  | 3.2 ± 6.87        |
| Limbic striatum      | 0.0189 ± 0.0016                                  | 8.71   | 0.0192 ± 0.0011                                  | 6.17   | 0.93  | 1.38 ± 4.01       |
| Associative striatum | 0.0196 ± 0.0019                                  | 9.94   | 0.0198 ± 0.0020                                  | 10.22  | 0.83  | 0.85 ± 7.85       |

CV: coefficient of variation; ICC: intraclass correlation coefficient; VAR: test-retest variability.

The system given the importance of these channels for regulating the activity of subsets of neurons in the basal ganglia. Positive modulation of Kv3.1 and Kv3.2 channels on GABA neurons in the VTA and substantia nigra may regulate the firing of DA neurons in these brain areas (Parekh et al., 2018). In behavioural studies, a Kv3.1/3.2-positive modulator compound, AUT1, reduced amphetamine-induced hyperactivity in mice to a similar degree to the antipsychotic drug clozapine (Hutchison et al., 2016; Parekh et al., 2018). The primary aim of the current study was to explore the potential for the Kv3.1/3.2-positive modulator, AUT00206 to influence DA synthesis capacity, as measured by $[^{18}F]$-FDOPA PET in patients with schizophrenia. Treatment with AUT00206 did not significantly reduce $K_i^{\text{est}}$. A significant reduction in symptom severity was observed in the AUT00206 but not in the placebo group, albeit the placebo group may have been underpowered to detect a significant effect.

There was a significant association between a reduction in $K_i^{\text{est}}$ and symptom improvement in the AUT00206 group. The apparently contradictory findings that $K_i^{\text{est}}$ was not significantly reduced by AUT00206 at a group level but there was a relationship between reduction in $K_i^{\text{est}}$ and symptom improvement at an individual level could be explained by AUT00206 acting to reduce DA synthesis capacity in some patients, who showed an improvement in symptoms, but having limited effect on DA synthesis capacity in other patients, who did not show an improvement in symptoms, resulting in an overall lack of group effect on $K_i^{\text{est}}$. These differences could be due to heterogeneity of pathophysiology in the patients in this study such that only a subset show an effect of AUT00206 treatment. For example, a subgroup of patients with schizophrenia have been found to not have elevated striatal $[^{18}F]$-DOPA uptake relative to controls, which was associated with non-response to antipsychotic treatment (Demjaha et al., 2012; Jauhar et al., 2019b). In the present study, all participants were within 5 years of diagnosis and not taking clozapine, but studies indicate that about 20% of patients show treatment resistance from first episode and a further 10–15% develop it during the course of illness (Demjaha, 2018; Kane et al., 2019). Thus, it is possible that we have included some treatment-resistant patients who do not show DA dysfunction.

It should also be noted that the study was powered to detect a large effect size change in $K_i^{\text{est}}$, and we cannot exclude smaller effects that may nevertheless be clinically meaningful. Furthermore, AUT00206 was added to up to two antipsychotic medications in this trial, so the potential for impact of the drug on clinical symptoms might have been limited. It was notable that we did not see a relationship between change in DA synthesis capacity and symptom improvement in the placebo group, which provides some support that the association observed in the AUT00206 group was a true drug effect; however, the study was not designed or powered for a comparison with placebo. A much larger study in patients with schizophrenia is needed to test whether there is a significant difference in this relationship between AUT00206.
and placebo. Future studies investigating the effects of AUT00206 as a control group of drug-free or drug-naïve patients, where the effects of AUT00206 can be measured as a stand-alone treatment, without interactions with other psychiatric medication. Furthermore, as AUT00206 does not act directly on DA receptors, it warrants further investigations using different radioligands to investigate its effects on other systems as well.

Conclusion

In contrast to our predictions, AUT00206 had no overall effect on DA synthesis capacity, although there was a direct relationship between reduction in DA synthesis capacity and improvement in symptoms. These findings support further investigation of the potential of the Kv3.1/Kv3.2 potassium channel modulator AUT00206 to treat schizophrenia. The test–retest reliability of [18F]-FDOPA PET imaging in patients with schizophrenia is very good across all functional striatal subdivisions.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Oliver D. Howes is a part-time employee of Lundbeck A/S and has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angellini, Astra-Zeneca, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Invicro, Janssen, Lundbeck, Lyden-Delta, Mylan, Neurocrine, Otsuka, Sunovion, Rand, Recordati, Roche and Viatris. Bill Deakin, Charles Large, John Hutchison, Alice Sharmar and Anil Sajjala are employed by Autifony Ltd. Faith Borgan became an employee at COMPASS Pathways plc after the completion of this work. This work is unrelated to COMPASS Pathways plc. Ilinca Angelescu, Stephen J. Kaar and Mattia Venosone have no conflicts of interest to declare.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by a grant to Oliver D. Howes from Innovate, UK, and from Autifony Ltd and Oliver D. Howes is supported by grants from Medical Research Council, UK (no. MC_U120097115), Wellcome Trust (no. 094849/10/0/Z) and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. Autifony Ltd was the sponsor of this clinical trial and they were involved in study design, conduct and interpretation of the results. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

ORCID iDs

Ilinca Angelescu https://orcid.org/0000-0003-3168-6378

Stephen J. Kaar https://orcid.org/0000-0003-0194-0806

Supplemental material

Supplemental material for this article is available online.

References

Abdallah CG, De Feyter HM, Averill LA, et al. (2018) The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43: 2154–2160.

Abi-Dargham A (2017) A dual hit model for dopamine in schizophrenia. Biol Psychiatry 81: 2–4.

Andrade-Talavera Y, Arroyo-Garcia LE, Chen G, et al. (2020) Modulation of Kv3.1/Kv3.2 potassium channels in the dorsolateral prefrontal cortex of subjects with schizophrenia. J Physiol 598: 3711–3725.

Beck K, Borgan F, McCutcheon R, et al. (2019) The effect of ketamine on psychopathology and implications for understanding schizophrenia: A meta-analysis. Eur Neuropsychopharmacol 29: S611.

Beck K, Hindley G, Borgan F, et al. (2020) Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: A systematic review and meta-analysis. JAMA Netw Open 3: e204693.

Berretta S, Pantazopoulos H, Markota M, et al. (2015) Losing the sugar coating: Potential impact of perineuronal net abnormalities on inter-neurons in schizophrenia. Schizophr Res 167: 18–27.

Boddu K, Hougaard C, Xiao-Ying Lin J, et al. (2017) Kv3.1/Kv3.2 potassium channel positive modulators enable faster activating kinetics and increase firing frequency in fast-spiking GABAergic interneurons. Neuropsychopharmacology 118: 102–112.

Bose SK, Turkheimer FE, Howes OD, et al. (2008) Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res 106: 148–155.

Chung DW, Volk DW, Arion D, et al. (2016) Dysregulated ErbB4 splicing in schizophrenia: Selective effects on parvalbumin expression. Am J Psychiatry 173: 60–68.

Cuming P, Leger GC, Kuwabara H, et al. (1993) Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F] Fdopa) in humans. J Cereb Blood Flow Metab 13: 668–675.

Deakin B, Perini F, Nazimek J, et al. (2019) T108. AUT00206, a novel Kv3 channel modulator, reduces ketamine-induced blood signalling in healthy male volunteers: A randomised placebo-controlled crossover trial. Schizophr Bull 45: S245–S246.

Demjaha A (2018) On the brink of precision medicine for psychosis: Treating the patient, not the disease: A commentary on: Association between serum levels of glutamate and neurotransmitter factors and response to clozapine treatment by Krivoy et al. 2017. Schizophr Res 193: 487–488.

Demjaha A, Murray RM, McGuire PK, et al. (2012) Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169: 1203–1210.

Dong E, Ruzicka WB, Grayson DR, et al. (2015) DNA-methyltransferase-1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. Schizophr Res 167: 35–41.

Egerton A, Demjaha A, McGuire P, et al. (2010) The test–retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 50: 524–531.

Enwright JF, Sanapala S, Foglio A, et al. (2016) Reduced labeling of parvalbumin neurons and perineuronal nets in the dorsolateral prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology 41: 2206–2214.

Faul F, Erdfelder E, Buchner A, et al. (2009) Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 41: 1149–1160.

First MB (2016) Structured clinical interview for the DSM (SCID–5-CV). Arlington, VA: American Psychiatric Association.

Frankle WG, Cho RY, Prasad KM, et al. (2015) In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients. Am J Psychiatry 172: 1148–1159.

Grace AA (2016) Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci 17: 524–532.

Gustavsson A, Svensson M, Jacob F, et al. (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 718–779.

Haaf M, Leicht G, Curic S, et al. (2018) Glutamatergic deficits in Schizophrenia–Biomarkers and pharmacological interventions within the ketamine model. Curr Pharm Biotechnol 19: 293–307.
Howes O, Bose S, Turkheimer F, et al. (2011a) Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study. Mol Psychiatry 16: 885–886.

Howes O, McCutcheon R and Stone J (2015) Glutamate and dopamine in schizophrenia: An update for the 21st century. J Psychopharmacol 29: 97–115.

Howes OD, Bose SK, Turkheimer F, et al. (2011b) Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168: 1311–1317.

Howes OD, Kambeitz J, Kim E, et al. (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies. Arch Gen Psychiatry 69: 776–786.

Howes OD, McCutcheon R, Agid O, et al. (2017) Treatment-resistant schizophrenia: Treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174: 216–229.

Howes OD, Montgomery AJ, Asselin M-C, et al. (2009) Elevated striatal dopamine function linked to prodomal signs of schizophrenia. Arch Gen Psychiatry 66: 13–20.

Howes OD and Murray RM (2014) Schizophrenia: An integrated sociodevelopmental-cognitive model. The Lancet 383: 1677–1687.

Howes OD, Williams M, Ibrahim K, et al. (2013) Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study. Brain 136: 3242–3251.

Hutchison J, Howes O, Marques TR, et al. (2019) 32.4 A novel treatment for cognitive impairment associated with schizophrenia by enhancing the activity of parvalbumin interneurons. Schizophr Bull 45: S142–S143.

Hutchison J, Sajjala A, Sahgal O, et al. (2016) Early clinical evaluation of AUT00206, a novel selective Kv3 channel modulator for the treatment of schizophrenia. Neuropsychopharmacology 41: S386–S386.

Jauhar S, Nour MM, Veronese M, et al. (2017) A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 74: 1206–1213.

Jauhar S, Veronese M, Nour MM, et al. (2019a) The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: A positron emission tomography study. Biol Psychiatry 85: 79–87.

Jauhar S, Veronese M, Nour MM, et al. (2019b) Determinants of treatment response in first-episode psychosis: An 18 F-DOPA PET study. Mol Psychiatry 24: 1502–1512.

Kaan SJ, Angelescu I, Marques TR, et al. (2019) Pre-frontal parvalbumin interneurons in schizophrenia: A meta-analysis of post-mortem studies. J Neural Transm 126: 1637–1651.

Kane JM, Agid O, Baldwin ML, et al. (2019) Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 80: 18com1223.

Kay SR, Fiszbein A and Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.

Kokkinou M, Irvine EE, Bonsall DR, et al. (2020) Reproducing the dopaminergic wiring of Schizophrenia: A meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull 44: 1301–1311.

McCutcheon RA, Abi-Dargham A and Howes OD (2019) Schizophrenia, dopamine and the striatum: From biology to symptoms. Trends Neurosci 42: 205–220.

McCutcheon RA, Krystal JH and Howes OD (2020a) Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment. World Psychiatry 19: 15–33.

McCutcheon RA, Marques TR and Howes OD (2020b) Schizophrenia: An overview. JAMA Psychiatry 77: 201–210.

McGraw KO and Wong SP (1996) Forming inferences about some intra-class correlation coefficients. Psychol Methods 1: 30–46.

Miyamoto S, Miyake N, Jarskog L, et al. (2012) Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17: 1206–1227.

Neill JC, Barnes S, Cook S, et al. (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacol Ther 128: 419–432.

Parekh PK, Sidor MM, Gillman A, et al. (2018) Antimanic efficacy of a novel Kv3 potassium channel modulator. Neuropsychopharmacology 43: 435–444.

Pratt J, Winchester C, Egerton A, et al. (2008) Modelling prefrontal cortex deficits in schizophrenia: Implications for treatment. Br J Pharmacol 153: S465–S470.

Reith J, Benkelfat C, Sherwin A, et al. (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci 91: 11651–11654.

Rosato-Siri MD, Zambello E, Mutinelli C, et al. (2015) A novel modulator of Kv3 potassium channels regulates the firing of parvalbumin-positive cortical interneurons. J Pharmacol Exp Ther 354: 251–260.

Schubert KG, Föcking M and Cotter DR (2015) Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: Potential roles in GABAergic interneuron pathology. Schizophr Res 167: 66–72.

Shrout PE and Fleiss JL (1979) Intraclass correlations: Uses in assessing rater reliability. Psychol Bull 86: 420–428.

Thembs S, Leicht G, Curic S, et al. (2017) Glutamatergic and schizophrenia-like negative symptoms: New evidence from ketamine-induced mismatch negativitiy alterations in healthy male humans. J Psychiatry Neurosci 42: 273–283.

Turkheimer FE, Brett M, Vizvikis D, et al. (1999) Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 19: 1189–1208.

Van T, Allen C, Arora M, et al. (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global burden of disease study 2015. Lancet 388: 1545–1622.

Whiteford HA, Degenhardt L, Rehm J, et al. (2013) Global burden of disease attributable to mental and substance use disorders: Findings from the global burden of disease study 2010. Lancet 382: 1575–1586.

Yanagi M, Joho RH, Southcott SA, et al. (2014) Kv3.1-containing K+ channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Mol Psychiatry 19: 573–579.